Patents Assigned to Merck Frosst Canada, Inc.
  • Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
    Patent number: 6486194
    Abstract: The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: November 26, 2002
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien
  • Methods of identifying modulators of prostaglandin receptor EP1
    Patent number: 6440680
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: September 13, 1999
    Date of Patent: August 27, 2002
    Assignees: Merck Frosst Canada, Inc., Vanderbuilt University
    Inventors: Anthony Ford-Hutchinson, Colin Funk, Richard Grygorczyk, Kathleen Metters
  • Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
    Publication number: 20010016595
    Abstract: The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor.
    Type: Application
    Filed: February 28, 2001
    Publication date: August 23, 2001
    Applicant: Merck Frosst Canada Inc./Merck Frosst Canada & Co.
    Inventors: Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien
  • 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor
    Patent number: 6239173
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: May 29, 2001
    Assignee: Merck Frosst Canada Inc./Merck Frosst Canada & Co.
    Inventors: Zhaoyin Wang, Michel Therien
  • Purified prostaglandin receptor EP1
    Patent number: 6031079
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: February 29, 2000
    Assignees: Merck Frosst Canada, Inc., Vanderbilt University
    Inventors: Anthony Ford-Hutchinson, Richard Grygorczyk, Collin Funk, Kathleen Metters
  • (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
    Patent number: 6020343
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: February 1, 2000
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel Belley, Jacques Yves Gauthier, Erich Grimm, Yves LeBlanc, Chun-Sing Li, Michel Therien, Cameron Black, Petpiboon Prasit, Cheuk-Kun Lau, Patrick Roy
  • Pyridazinones as inhibitors of cyclooxygenase-2
    Patent number: 6004960
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: March 13, 1998
    Date of Patent: December 21, 1999
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Chun Sing Li, Jacques Y. Gauthier, Cheuk K. Lau, Michel Therien
  • 2-aminopyridines as inhibitors of cyclooxygenase-2
    Patent number: 6004950
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: September 11, 1998
    Date of Patent: December 21, 1999
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Richard Friesen, Daniel Dube, Denis Deschenes
  • Bisaryl COX-2 inhibiting compounds, compositions and methods of use
    Patent number: 5994379
    Abstract: The present invention relates to inhibitors of COX-2, compositions which contain such compounds and methods of use. The compounds are represented by formula I: ##STR1## and include pharmaceutically acceptable salts and esters thereof.
    Type: Grant
    Filed: February 9, 1999
    Date of Patent: November 30, 1999
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Christopher I. Bayly, Cameron Black, Nathalie Ouimet, David Percival, Serge Leger, Marc Ouellet
  • DNA encoding prostaglandin receptor EP1
    Patent number: 5985597
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: May 26, 1993
    Date of Patent: November 16, 1999
    Assignees: Merck Frosst Canada, Inc., Vanerbilt University
    Inventors: Anthony Ford-Hutchinson, Colin Funk, Richard Grygorczyk, Kathleen Metters
  • (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
    Patent number: 5981576
    Abstract: The invention encompasses the novel compound of Formula A that is useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula A.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: November 9, 1999
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel Belley, Jacques Yves Gauthier, Erich Grimm, Yves LeBlanc, Chun-Sing Li, Michel Therien, Cameron Black, Petpiboon Prasit, Cheuk-Kun Lau, Patrick Roy
  • 5-Methanesulfonamido-3H-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
    Patent number: 5968958
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: October 19, 1999
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Daniel Guay, Chun-Sing Li, Nathalie Ouimet
  • DNA encoding prostaglandin receptor FP
    Patent number: 5869281
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: June 25, 1993
    Date of Patent: February 9, 1999
    Assignee: Merck Frosst Canada Inc.
    Inventors: Mark Abramovitz, Richard Grygorczyk, Kathleen Metters, Truyen Nguyen, Thomas H. Rushmore, Deborah Slipetz
  • Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
    Patent number: 5856322
    Abstract: Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.
    Type: Grant
    Filed: February 8, 1996
    Date of Patent: January 5, 1999
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel L. Belley, Serge Leger, Patrick Roy, Marc Labelle, Yi Bin Xiang, Daniel Guay
  • Stilbene derivatives useful as cyclooxygenase-2 inhibitors
    Patent number: 5849943
    Abstract: The invention encompasses novel compounds of Formula Iuseful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceuticalcompositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I.
    Type: Grant
    Filed: April 7, 1997
    Date of Patent: December 15, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Joseph Atkinson, Zhaoyin Wang
  • Purified prostaglandin receptor FP
    Patent number: 5840847
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: November 24, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Mark Abramovitz, Richard Grygorczyk, Kathleen Metters, Truyen Nguyen, Thomas H. Rushmore, Deborah Slipetz
  • Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
    Patent number: 5840746
    Abstract: The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: November 24, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien
  • Method for identifying inhibitors for apopain based upon the crystal structure of the apopain: Ac-DEVD-CHO complex
    Patent number: 5834228
    Abstract: The apopain:Ac-DEVD-CHO complex has been crystallized and its structure determined by x-ray crystallography. Based upon this crystal structure of the complex, a method for identifying inhibitors of apopain is presented which comprises designing putative inhibitors having specific contacts with apopain, making the putative inhibitors, and testing the putative inhibitors for their ability to inhibit apopain.
    Type: Grant
    Filed: February 13, 1997
    Date of Patent: November 10, 1998
    Assignees: Merck & Co., Inc., Merck Frosst Canada, Inc.
    Inventors: Joseph W. Becker, Donald W. Nicholson, Jennifer Rotonda, Nancy A. Thornberry, Kimberly M. Fazil, Michel Gallant, Yves Gareau, Marc Labelle, Erin P. Peterson, Dita M. Rasper, Rejean Ruel, John P. Vaillancourt
  • Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
    Patent number: 5817700
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: October 6, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Daniel Dube, Rejean Fortin, Richard Frenette, Richard Friesen, Daniel Guay, Sylvie Prescott
  • Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
    Patent number: 5798442
    Abstract: Compounds having the formula I:R.sup.1 COAA.sup.1 AA.sup.2 AA.sup.3 NHYare inhibitors of apopain, an enzyme involved in the process of apoptosis. These compounds are useful as research tools as well as in the treatment of any condition in which reduced apoptosis would be beneficial, including immune deficiency syndromes (including AIDS), type I diabetes, pathogenic infections, cardiovascular and neurological injury, alopecia, aging, Parkinson's disease and Alzheimer's disease.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: August 25, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel Gallant, Marc Labelle, Yves Gareau, Donald W. Nicholson